INTRODUCTION Over the past several decades, the number of therapeutic options for patients with relapsed/recurrent Ewing sarcoma (RR-ES) has significantly increased, leading to ambiguity in the management strategies for this patient population.1 It is clear that treatment of patients with relapsed disease should be geared toward maximizing outcomes, reducing toxicities, and supporting the patient's goals for care.
Bela Kis
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Bela
Contact Bela, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack